100-Year evolution of precision medicine and surgery for multiple endocrine neoplasia type 2A.

doi:10.1007/s12020-020-02232-5

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

100-Year evolution of precision medicine and surgery for multiple endocrine neoplasia type 2A.

Endocrine - 1 May 2020

Machens Andreas, Elwerr Malik, Lorenz Kerstin, Weber Frank, Dralle Henning

Abstract excerpt

PURPOSE: To determine whether published disease penetrance estimates of 50% for pheochromocytoma and 20-30% for primary hyperparathyroidism in multiple endocrine neoplasia (MEN 2A), conceivably reflecting overrepresentation of index patients with completely developed MEN 2A, may be too high. METHODS: Cross-sectional study of carriers at high risk of MEN 2A from a tertiary referral center. RESULTS: There were 213...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adrenal Gland Neoplasms
Share to Carcinoma, Medullary
Share to Cross-Sectional Studies
Share to Multiple Endocrine Neoplasia Type 2a

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Precision Medicine

Share to Proto-Oncogene Mas

Share to Proto-Oncogene Proteins c-ret

Share to Thyroid Neoplasms

Source

Open in PubMed

Identifiers

PMID: 32100189
DOI: 10.1007/s12020-020-02232-5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.